Abstract
The pandemic 2009 H1N1 influenza virus broke out in North America and spread rapidly throughout the world. The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, the protective potential of human exogenous IFN-ω against pandemic 2009 A (H1N1) influenza virus was assessed both in vitro and in guinea pigs. The viral loads of pandemic 2009 A (H1N1) influenza virus strains A/California/04/2009 and A/Beijing/501/2009 were reduced by up to 5000-fold in Caco-2 cells by the addition of human IFN-ω. With daily intranasal treatment with human IFN-ω the viral load of pandemic 2009 A (H1N1) influenza virus strain A/California/04/2009 decreased by 1000-fold in lung tissues of guinea pigs. These results provide strong support for the application of human IFN-ω pretreatment to human influenza control.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intranasal
-
Animals
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use
-
Caco-2 Cells
-
Cell Line
-
Disease Models, Animal
-
Female
-
Guinea Pigs
-
Humans
-
Influenza A Virus, H1N1 Subtype / drug effects*
-
Influenza A Virus, H1N1 Subtype / immunology
-
Influenza A Virus, H1N1 Subtype / pathogenicity
-
Interferon Type I / administration & dosage*
-
Interferon Type I / genetics
-
Interferon Type I / pharmacology
-
Interferon Type I / therapeutic use
-
Lung / virology
-
Orthomyxoviridae Infections / drug therapy*
-
Orthomyxoviridae Infections / pathology
-
Orthomyxoviridae Infections / virology
-
Pandemics*
-
Recombinant Proteins / administration & dosage*
-
Recombinant Proteins / genetics
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
Interferon Type I
-
Recombinant Proteins
-
interferon omega 1